{"title":"地西他滨治疗血液病的研究进展","authors":"Lang Peng","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.01.012","DOIUrl":null,"url":null,"abstract":"Studies show that DNA methylation play an important role during the transformation of hematopoitic diseases. Decitabine is a kind of demethylation drug that can inhibit DNA methyltransferase. Currently, decitabine is mainly used to treat hematological diseases, such as myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), etc., due to its unique mechanisms and better clinical effectiveness. In recent years, decitabine is also used for steroid-resistant/refractory primary immune thrombocytopenia (ITP) patients, which can improve platelet count, reduce bleeding risk and improve patients′ prognosis. In order to explore the clinical application of decitabine, this article summarizes the research progress on decitabine for treatment of hematopoietic disease. \n \n \nKey words: \nMyelodysplastic syndromes; Hematologic diseases; Leukemia, myeloid; Purpura, thrombocytopenic, idiopathic; Decitabine","PeriodicalId":13774,"journal":{"name":"国际输血及血液学杂志","volume":"42 1","pages":"72-78"},"PeriodicalIF":0.0000,"publicationDate":"2019-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Research progress of decitabine in treatment of hematologic diseases\",\"authors\":\"Lang Peng\",\"doi\":\"10.3760/CMA.J.ISSN.1673-419X.2019.01.012\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Studies show that DNA methylation play an important role during the transformation of hematopoitic diseases. Decitabine is a kind of demethylation drug that can inhibit DNA methyltransferase. Currently, decitabine is mainly used to treat hematological diseases, such as myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), etc., due to its unique mechanisms and better clinical effectiveness. In recent years, decitabine is also used for steroid-resistant/refractory primary immune thrombocytopenia (ITP) patients, which can improve platelet count, reduce bleeding risk and improve patients′ prognosis. In order to explore the clinical application of decitabine, this article summarizes the research progress on decitabine for treatment of hematopoietic disease. \\n \\n \\nKey words: \\nMyelodysplastic syndromes; Hematologic diseases; Leukemia, myeloid; Purpura, thrombocytopenic, idiopathic; Decitabine\",\"PeriodicalId\":13774,\"journal\":{\"name\":\"国际输血及血液学杂志\",\"volume\":\"42 1\",\"pages\":\"72-78\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-01-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"国际输血及血液学杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.01.012\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"国际输血及血液学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.01.012","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Research progress of decitabine in treatment of hematologic diseases
Studies show that DNA methylation play an important role during the transformation of hematopoitic diseases. Decitabine is a kind of demethylation drug that can inhibit DNA methyltransferase. Currently, decitabine is mainly used to treat hematological diseases, such as myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), etc., due to its unique mechanisms and better clinical effectiveness. In recent years, decitabine is also used for steroid-resistant/refractory primary immune thrombocytopenia (ITP) patients, which can improve platelet count, reduce bleeding risk and improve patients′ prognosis. In order to explore the clinical application of decitabine, this article summarizes the research progress on decitabine for treatment of hematopoietic disease.
Key words:
Myelodysplastic syndromes; Hematologic diseases; Leukemia, myeloid; Purpura, thrombocytopenic, idiopathic; Decitabine
期刊介绍：
The International Journal of Transfusion and Hematology was founded in September 1978. It is a comprehensive academic journal in the field of transfusion and hematology, supervised by the National Health Commission and co-sponsored by the Chinese Medical Association, West China Second Hospital of Sichuan University, and the Institute of Transfusion Medicine of the Chinese Academy of Medical Sciences. The journal is a comprehensive academic journal that combines the basic and clinical aspects of transfusion and hematology and is publicly distributed at home and abroad. The International Journal of Transfusion and Hematology mainly reports on the basic and clinical scientific research results and progress in the field of transfusion and hematology, new experiences, new methods, and new technologies in clinical diagnosis and treatment, introduces domestic and foreign research trends, conducts academic exchanges, and promotes the development of basic and clinical research in the field of transfusion and hematology.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
